about
Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation.Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial.Bendamustine as monotherapy and in combination regimens for the treatment of chronic lymphocytic leukemia and non-hodgkin lymphoma: a retrospective analysis.Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup studyAn international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.Treatment of older patients with mantle-cell lymphoma.Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.Autologous stem cell transplantation as consolidation therapy for patients with peripheral T cell lymphoma in first remission: long-term outcome and risk factors analysis.Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network.Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia.Current Treatment of Chronic Lymphocytic Leukemia.Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia.Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients.Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials.Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study.Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell LympTreatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy.Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network.CHOP-21 for unfavorable Hodgkin's lymphoma. An exploratory study.Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519).Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma.Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations.A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration.The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients-the Polish Lymphoma Research Group (PLRG) Observational Study.Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Comparision of benefits of early, delayed, and no administration of G-CSF after autologous peripheral blood stem cell transplantation in lymphoma patients.Unusual cyclin D1 positive marginal zone lymphoma of mediastinum.Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
P50
Q27690791-A1889BD5-9C85-4885-8C22-C7DEF498613DQ33396066-D6269E2F-39F3-42C8-B238-A170C76407A3Q33403958-1DF539DE-4D3A-4EFE-AE75-B1414827D741Q33412849-7F4555AD-F65D-4E6F-8E3F-A2CD54EAF305Q33423816-8480FE52-8998-4ACD-A90E-1D274C10AE33Q33430165-E6F19688-BFB9-49B0-BEBE-A0821BFDC8A1Q33885555-766D1E2A-7AED-4249-9233-BAAA69786291Q34095473-84B0C9CE-C86B-4E1D-8623-761B5F4D9D19Q34526281-5BDCA498-BBC7-4AA5-8009-4C732F42DDA8Q34625316-CFABDD98-A292-44F3-A8DC-4A96D12371C6Q34641279-93B80CE2-D8E7-4149-BDC3-807E14D2E9EDQ34711661-A019EAD3-D54D-4003-ABE0-E6A8B87CED25Q36495967-6081BC0A-C293-488B-BC72-3CB033D81DDBQ36907048-3F0E2855-8D6C-41A3-BDD4-AB39F573A68EQ37919520-DA0AA906-82AE-43AE-BEE4-8E1D0AFBD729Q38386440-32B23284-37FA-4FC4-AE9E-0564515079D8Q38917132-D965A6C4-3973-41B4-A776-B90DB434EE5EQ39129372-A444C475-8853-4C0D-B60C-2200A04BB945Q39363280-D6DAA8BC-8FFA-46A1-B0D1-916DF347DE9AQ39532967-14473321-D0EE-4506-B68B-C7E2BED3811EQ40149390-E2651A40-DD9A-4169-A132-A94789E04132Q40284895-F8E3D076-0771-4F30-891E-BC44DA4B23F6Q40590761-E048258C-B287-4348-8BED-7E02D0AC1BCBQ40696072-19237502-5674-402D-B143-F81F18671AA4Q44892761-90A0F059-3C3C-4A24-8251-88772C0AA293Q45097226-B3259FE3-6514-4FE5-BE72-B22E5AF43D8EQ45993077-C627E892-20B5-4CA9-8A28-F5D618682355Q46075729-7A1963D4-44F5-4E4C-8502-F75415E4DD30Q46825132-41D77FEB-D0C0-4825-8405-226523D0DECEQ47097358-0684138D-19E4-41CA-BADF-3AABAF1D4FA8Q47387312-5ADAA11B-5FF8-4581-88BC-92ECF0535D6BQ47563175-82CB3CC8-7844-4EFD-947F-426B2A1BEC21Q48083818-C19BB4D1-1A6B-463B-8B44-2309EACF954EQ48238170-DCF27170-35A8-4FF8-8E7B-7DE9C06F2DB3Q48254769-21D7450B-F690-420C-BEDC-E030E9F9DE42Q49821096-4985304F-118F-466C-AA60-9A188C75D7FAQ50205176-91E167C9-653F-470A-9AED-61B7B0424BA2Q50865088-902F95BD-8E87-465C-AD0B-2BBD3581C1BAQ51782411-CD29C998-74CE-43C7-A580-B930D42C8E41Q52836250-8454763B-8F85-423B-9997-022068177FC5
P50
description
Polish oncologist and researcher
@en
Pools onderzoeker
@nl
cercetător polonez
@ro
chercheur polonais
@fr
investigador polaco
@es
investigador polaco
@gl
investigador polonès
@ca
polnischer Forscher
@de
polski onkolog
@pl
ricercatore polacco
@it
name
Jan Walewski
@ast
Jan Walewski
@ca
Jan Walewski
@de
Jan Walewski
@en
Jan Walewski
@es
Jan Walewski
@fr
Jan Walewski
@ga
Jan Walewski
@gl
Jan Walewski
@it
Jan Walewski
@nl
type
label
Jan Walewski
@ast
Jan Walewski
@ca
Jan Walewski
@de
Jan Walewski
@en
Jan Walewski
@es
Jan Walewski
@fr
Jan Walewski
@ga
Jan Walewski
@gl
Jan Walewski
@it
Jan Walewski
@nl
altLabel
Jan Andrzej Walewski
@pl
prefLabel
Jan Walewski
@ast
Jan Walewski
@ca
Jan Walewski
@de
Jan Walewski
@en
Jan Walewski
@es
Jan Walewski
@fr
Jan Walewski
@ga
Jan Walewski
@gl
Jan Walewski
@it
Jan Walewski
@nl
P1153
7003726282
P1412
P1559
Jan Walewski
@pl
P21
P27
P31
P3124
P496
0000-0003-4247-2674